However, the expression of β3-AR by cells of the fetal cardiovascular system makes this latter apparatus a possible target of β3-AR blockers and, hence, an Achilles heel of possible anti-cancer treatments based on these drugs. The gene discussed is ADRB3; the disease is cancer.